Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
Conference Investment Track spotlights promising and emerging biotech and healthcare companies advancing the field of oncology
SAN JOSE, Calif. , Jan. 29, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the 2024 NeauxCancer Conference organized by the Cancer Advocacy Group of Louisiana (CAGLA), being held February 29 – March 2, 2024 in New Orleans. Anixa Chairman and CEO Dr. Amit Kumar will present and meet one-on-one with investors throughout the day on Friday, March 1st.
Related news for (ANIX)
- Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
- MoBot alert highlights: NASDAQ: XTLB, NASDAQ: QTTB, NASDAQ: BIAF, NASDAQ: ANIX, NASDAQ: NERV (10/07/25 07:00 PM)
- MoBot’s Stock Market Highlights – 10/07/25 03:00 PM
- 24/7 Market News Snapshot 07 October, 2025 – Anixa Biosciences, Inc. (NASDAQ:ANIX)
- Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial